NCT05886933View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet

CompletedOBSERVATIONAL
Enrollment

9,846

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2024

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

Fexuprazan Hydrochloride

Patient treated with Fexuprazan Hydrochloride (Fexuclue Tablet)

Trial Locations (1)

Unknown

Co&Ping Otolaryngology Clinic, Busan

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT05886933 - Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet | Biotech Hunter | Biotech Hunter